The company’s matching strategy for CB-010 will soon be put to the test.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.

Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.

For now, the group is sticking with what it knows ahead of a big year in lymphoma.

The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.

Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.